Eli Lilly and Company has taken the lead in in the development and tirzepatide, a groundbreaking drug for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, showcases significant capacity to improve https://haseebqwbo628266.blogsuperapp.com/37951367/eli-lilly-s